Key points from article :
Bayer and Hurdle have formed a strategic partnership to revolutionise precision health, with a focus on the rapidly growing market for healthy ageing solutions. Announced on November 28, 2023, in San Francisco, USA, and Basel, Switzerland, this collaboration aims to advance consumer innovations by merging Hurdle’s cutting-edge diagnostic technology with Bayer’s expertise in developing consumer health products and its extensive global presence.
A key element of this partnership is the introduction of Hurdle’s saliva-based Chronomics Biological Age Test, which will be available directly to consumers through e-commerce platforms. This test utilises epigenetic biomarkers to provide a personalised assessment of biological age, empowering individuals with data-driven insights into their unique ageing process. The initiative aligns with the broader trend toward precision health, where personalised health information enables consumers to make informed decisions about their well-being.
Bayer emphasises the importance of understanding that the ageing process varies for each person, influenced by factors like environment, lifestyle, and genetics. The partnership with Hurdle aims to provide consumers with scientific data that helps them proactively manage their health as they age.
Hurdle’s advanced technology, which streamlines the complex process from biomarker discovery to consumer-ready products, plays a central role in this partnership. By working together, Bayer and Hurdle seek to accelerate the development and availability of personalised health solutions, advancing the science of biological age measurement.
This collaboration is in line with Bayer's strategic focus on precision health, supported by Hurdle's AI-powered biomarker discovery platform. Together, the companies are committed to transforming self-care by offering innovative tools that support healthy ageing, with the potential to redefine how ageing is approached in the years ahead.
